University of California

Liguang Chen

Thomas James Kipps

Bing Cui

Jian Yu

George F Widhopf, Ii

Charles E Prussak

Suping Zhang

Tetsuya Fukuda

Tomoyuki Endo

H Elizabeth Broome

Charles Prussak

George Widhopf

The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.

Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.

Cancer treatment combinations

Compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates and anti-sera that specifically bind to or are otherwise directed against ROR1 protein. The compositions may be used for detecting ROR1 in a sample from a subject that is suspected or known to contain cancer cells. The ROR1 antibodies are especially useful in identifying and treating lymphomas and ademocarcinomas. Vaccines and related methods for protecting a subject against diseases that involve expression of ROR1 are also provided, as are human anti-sera effective in abrogating interactions between Wnt5a protein and ROR1 that contribute to the survival of certain cancer cells, such as CLL cells.

Methods and compounds for lymphoma cell detection and isolation

Growing community of inventors

San Diego, CA, United States of America

Liguang Chen